Veradermics (MANE) net assets (shareholders' equity)
Veradermics (MANE) had net assets of $143.46M at the end of fiscal 2025 (December 31, 2025). That is 182.3% higher than the $50.82M of fiscal 2024. Figures as of 19 Nov 2026, 00:21 UTC, from Yahoo Finance.
Key facts
- Net assets, fiscal 2025
- $143.46M
- Change on fiscal 2024
- +182.3%
- Highest on record
- $143.46Mfiscal 2025
- Lowest on record
- $13.72Mfiscal 2023
- Fiscal years on record
- 32023–2025
Figures as of . Statements from Yahoo Finance. Amounts are in USD. Figures, not advice.
Veradermics net assets (shareholders' equity), in more detail
Across the 3 fiscal years on record (2023–2025), the highest was $143.46M in fiscal 2025 and the lowest $13.72M in fiscal 2023.
Net assets by fiscal year
Veradermics net assets (shareholders' equity), year by year
| Fiscal year | Net assets | Change | Year ended |
|---|---|---|---|
| 2025 | $143.46M | 182.3% up | |
| 2024 | $50.82M | 270.3% up | |
| 2023 | $13.72M | — |
Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
Net assets is shareholders' equity on the balance sheet at the fiscal year-end: total assets minus total liabilities, also called book value.
How to read it
Large buybacks and write-offs shrink it without the business getting worse, so a falling or negative figure needs the reason before a verdict.
Net assets at health care companies of similar size
| Company | Net assets | Fiscal year |
|---|---|---|
| Scholar Rock Holding SRRK | $245.49M | 2025 |
| Teleflex TFX | $3.12B | 2025 |
| Mirum Pharmaceuticals MIRM | $314.69M | 2025 |
| Veradermics MANE | $143.46M | 2025 |
| Grifols GRFS | €5.27B | 2025 |
| Cogent Biosciences COGT | $636.37M | 2025 |
The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.
Veradermics, figure by figure
- Veradermics market cap
- Veradermics revenue
- Veradermics earnings
- Veradermics earnings per share (EPS)
- Veradermics P/E ratio
- Veradermics P/S ratio
- Veradermics P/B ratio
- Veradermics free cash flow
- Veradermics operating margin
- Veradermics dividend
- Veradermics shares outstanding
- Veradermics total debt
- Veradermics cash on hand
- Veradermics total assets
- Veradermics total liabilities
- Veradermics return on equity (ROE)
- Veradermics return on invested capital (ROIC)
Veradermics (MANE) overview: price, valuation and scorecardAll health care companies by market value
Veradermics net assets (shareholders' equity): questions and answers
What are Veradermics's net assets?
Veradermics (MANE) had net assets of $143.46M at the end of fiscal 2025 (December 31, 2025). That is 182.3% higher than the $50.82M of fiscal 2024.
What are the highest and lowest net assets figures on record for Veradermics?
Across the 3 fiscal years on record (2023–2025), the highest was $143.46M in fiscal 2025 and the lowest $13.72M in fiscal 2023.
How is Veradermics's net assets calculated?
Net assets is shareholders' equity on the balance sheet at the fiscal year-end: total assets minus total liabilities, also called book value. For Veradermics it is on record here for 3 fiscal years, 2023 to 2025.
Fiscal years are named for the calendar year they end in.
Learn: net assets (shareholders' equity)
All stocks guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Market cap vs enterprise value: what is the difference?
Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
Cite this page
Funkfolio, “Veradermics (MANE) net assets (shareholders' equity)”, data as of 19 November 2026. https://funkfolio.com/stock/MANE/net-assets
Underlying data: Yahoo Finance.